Dr Shiu is a Consultant in the Gastrointestinal Oncology Unit at University College London Hospital and Honorary Associate Professor at the UCL Cancer Institute. He qualified at Guys and St Thomas’ Medical School, training in medical oncology at the Royal Free Hospital and UCLH. He completed his PhD in integrative genomic profiling of cancer at the Institute of Cancer Research and the Royal Marsden Hospital. He also attained a research fellowship at the MRC Clinical Trials Unit at UCL as a member of the FOCUS4 Colorectal Trial Management Group. He was awarded Fellowship of the Royal College of Physicians, London in 2019.
His research interests include immunotherapy for GI malignancies and Cancer of Unknown Primary, as well as the development of novel cancer clinical trial designs. He is the UK Chief Investigator or Principal Investigator for a number of national and international gastrointestinal immuno-oncology trials including VESTIGE, SURPASS-2, KEYNOTE 811, 859 and 975, LEAP 15, LEAP 17 and KEYNOTE 177. He is also the UK Chief Investigator for CUPISCO, a 1st line Phase 2 randomised molecular guided therapy trial for patients with CUP and Chief Investigator for the upcoming neoadjuvant immunotherapy NEOPRISM trial for operable MSI-High colorectal cancer.
Dr Shiu is Chair of the NCRI CUP Workstream and a member of the NCRI Colorectal Advanced and Adjuvant Disease Subgroup. He is a collaborator in the PEACE (Posthumous tissuE donAtion in CancEr) study, and a member of the Gastrointestinal Oncology and CUP subgroups at UCL Cancer Institute/Francis Crick Institute. He is the Principal Investigator of the UCL/UCLH Gastrointestinal Cancer Translational Research Biobank.